Clinical Trial Results: A Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluating Rocatinlimab in adolescents with moderate-to-severe atopic dermatitis have been completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Rocatinlimab (rocatinlimab)

Snippet

Sponsor: Amgen | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2026-07-24